Women's Health Weekly — 2026-06-16

Key Highlights

Hormone Therapy Shows Bone Protection Benefits

A new study finds that menopausal women taking hormone replacement therapy (HRT) were nearly 70 percent less likely to show signs of osteoporosis compared with women not taking it—potentially lowering the risk of fractures, disability, and early death.

Women's Health Magazine also highlighted this advantage, reporting that research continues to reshape how healthcare providers deliver care during menopause.

Culturally Informed Menopause Care Toolkit Launched

Researchers at the University of Liverpool have developed a new toolkit to help healthcare professionals deliver culturally informed menopause care. The work, highlighted in a correspondence published in The Lancet Obstetrics, Gynaecology & Women's Health, addresses a critical gap in care for women from minority ethnic communities experiencing menopause.

Women's Health Market Expands Rapidly

The global women's health market reached USD 44.1 billion in 2025 and is projected to expand to USD 60.4 billion by 2034, growing at a compound annual growth rate (CAGR) of 3.45 percent. The U.S. women's health market alone reached USD 52.02 billion in 2025 and is expected to reach USD 83.23 billion by 2033, with growth driven by hormonal and reproductive health solutions.

Analysis

This week's research underscores two critical shifts in women's health: expanding treatment options for menopause and greater recognition of disparities in care access. The hormone therapy findings address long-standing concerns about fracture risk in postmenopausal women, offering evidence-based reassurance for women weighing HRT benefits and risks. Simultaneously, the University of Liverpool toolkit reflects growing awareness that menopause experiences differ significantly across cultures—a gap that has been overlooked in mainstream medical research and practice.

The explosive market growth signals that both public health systems and private investors recognize women's health as a priority area. However, whether this expansion translates into equitable access for underserved populations—particularly women from minority ethnic backgrounds—remains an open question that the new toolkit begins to address.

What to Watch

Clinical trials on alternative menopause treatments for women who cannot take traditional HRT (such as those with breast cancer history) are expected to accelerate in the coming months, given that millions of women currently lack safe options.